Log in

NASDAQ:BMRNBioMarin Pharmaceutical Price Target & Analyst Ratings

-0.98 (-0.82 %)
(As of 08/7/2020 04:00 PM ET)
Today's Range
Now: $118.67
50-Day Range
MA: $124.31
52-Week Range
Now: $118.67
Volume754,347 shs
Average Volume1.04 million shs
Market Capitalization$21.52 billion
P/E Ratio179.80
Dividend YieldN/A

Analyst Ratings

BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target and Consensus Rating

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
23 Wall Street analysts have issued ratings and price targets for BioMarin Pharmaceutical in the last 12 months. Their average twelve-month price target is $125.27, suggesting that the stock has a possible upside of 5.56%. The high price target for BMRN is $156.00 and the low price target for BMRN is $77.00. There are currently 6 hold ratings and 17 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.742.732.772.88
Ratings Breakdown: 0 Sell Rating(s)
6 Hold Rating(s)
17 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
6 Hold Rating(s)
16 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
17 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $125.27$119.70$112.25$111.41
Price Target Upside: 5.56% upside6.47% downside17.91% upside31.66% upside

BioMarin Pharmaceutical (NASDAQ:BMRN) Consensus Price Target History

Average Share Price and Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

BioMarin Pharmaceutical (NASDAQ:BMRN) Analyst Ratings History

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/6/2020BMO Capital MarketsBoost Price TargetMarket Perform$94.00 ➝ $108.00Low
8/5/2020OppenheimerInitiated CoverageHold$116.00Low
8/5/2020WedbushReiterated RatingBuy$146.00Low
8/5/2020BarclaysBoost Price Target$125.00 ➝ $135.00Low
8/5/2020Piper SandlerBoost Price Target$120.00 ➝ $133.00Low
8/5/2020Credit Suisse GroupReiterated RatingBuy$128.00Medium
8/5/2020JPMorgan Chase & Co.Boost Price TargetOverweight$140.00 ➝ $156.00Low
8/5/2020SVB LeerinkBoost Price TargetOutperform$130.00 ➝ $140.00Low
7/24/2020Robert W. BairdBoost Price Target$125.00 ➝ $140.00Low
7/8/2020Morgan StanleyDowngradeOverweight ➝ Equal Weight$125.00Low
7/6/2020CitigroupBoost Price TargetBuy$105.00 ➝ $148.00Low
6/18/2020SunTrust BanksBoost Price Target$109.00 ➝ $143.00Low
6/10/2020Bank of AmericaBoost Price TargetBuy$120.00 ➝ $130.00Low
5/10/2020CfraReiterated RatingBuy$115.00Low
5/8/2020Canaccord GenuityBoost Price Target$108.00 ➝ $119.00Low
5/1/2020William BlairReiterated RatingBuyLow
4/30/2020NomuraReiterated RatingHold$77.00High
3/2/2020Nomura SecuritiesReiterated RatingHold$77.00Medium
1/24/2020Royal Bank of CanadaUpgradeSector Perform ➝ Outperform$111.00 ➝ $113.00Low
1/2/2020Raymond JamesDowngradeOutperform ➝ Market PerformLow
12/16/2019Cantor FitzgeraldReiterated RatingBuy$129.00Low
12/16/2019CowenReiterated RatingBuy$150.00Medium
9/13/2019Piper Jaffray CompaniesSet Price TargetBuy$120.00Medium
9/13/2019Stifel NicolausSet Price TargetBuy$108.00Medium
12/17/2018GuggenheimInitiated CoverageNeutralHigh
12/14/2018Wolfe ResearchInitiated CoverageOutperform ➝ OutperformMedium
10/16/2018Jefferies Financial GroupBoost Price TargetFair Value ➝ Buy$125.00High
4/30/2018Sanford C. BernsteinLower Price TargetMarket Perform$97.00 ➝ $92.00Medium
2/23/2018Deutsche BankSet Price TargetBuy ➝ Buy$119.00 ➝ $124.00High
12/15/2017Goldman Sachs GroupUpgradeBuy ➝ Conviction-BuyHigh
8/16/2017Evercore ISIInitiated CoverageOutperform ➝ Outperform$100.00High
(Data available from 8/10/2018 forward)
This page was last updated on 8/10/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.